Novartis Japan Faces Censure for Reporting Delays

According to an article in The Japan Times, the Ministry of Health, Labor and Welfare will censure a Japanese unit of Novartis AG for failing to report serious drug side effects.

The health ministry could serve Novartis Pharma K.K. with a business improvement order this month, the article said.

The case involves side effects from about 5,500 patients, which should have been reported within a few weeks. Read the full story